First characterisation of antimicrobial susceptibility and resistance of *Neisseria gonorrhoeae* isolates in Qatar, 2017-2020

Muna Al-Maslamani^{1§}, Emad Bashier Ibrahim Elmagboul^{1,2§}, Aslam Puthiyottil¹, Hiam Chemaitelly^{3,4}, Manoj Kizhakkepeedikayil Varghese¹, Hamad Eid Al Romaihi⁵, Mohamed H. Al-Thani⁵, Abdullatif Al Khal¹, Magnus Unemo^{6†*}, Laith J. Abu-Raddad^{3,4,7,8†*}

¹Hamad Medical Corporation, Doha, Qatar

²Biomedical Research Center, Qatar University, Doha, Qatar

³Infectious Diseases Epidemiology Group, Weill Cornell Medicine – Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar

⁴World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar

⁵Ministry of Public Health, Doha, Qatar

⁶WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, National Reference Laboratory for Sexually Transmitted Infections, Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

⁷Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York City, New York, USA

⁸Department of Public Health, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar

§Joint first authors.

†Joint senior authors.

Word count: Abstract: 200 words, Main Text: 1,774 words.

Number of tables: 1.

Number of figures: 1.

Running head: Gonococcal antimicrobial resistance in Qatar.

Funding: Biomedical Research Program at Weill Cornell Medicine – Qatar.

Correspondence to

Professor Laith J. Abu-Raddad, Infectious Disease Epidemiology Group, World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine - Qatar, Qatar Foundation - Education City, P.O. Box 24144, Doha, Qatar; lja2002@qatar-med.cornell.edu. Telephone: +(974) 4492-8321. Fax: +(974) 4492-8333.

Assoc Professor Magnus Unemo, WHO Collaborating Centre for Gonorrhoea and other STIs, Department of Laboratory Medicine, Örebro University Hospital, SE-70185 Örebro, Sweden; magnus.unemo@regionorebrolan.se. Telephone: +46-19-6022038.

ABSTRACT

Limited data are available regarding antimicrobial resistance in *Neisseria gonorrhoeae* strains circulating in WHO Eastern Mediterranean Region (EMR). We investigated the antimicrobial susceptibility/resistance of *N. gonorrhoeae* isolates to five antimicrobials (ceftriaxone, azithromycin, ciprofloxacin, tetracycline, and benzylpenicillin) currently or previously used for gonorrhoea treatment in Qatar, 2017-2020. Minimum inhibitory concentrations (MICs; mg/L) of antimicrobials were determined using Etest on gonococcal isolates collected during January 1, 2017-August 30, 2020 at Hamad Medical Corporation, a national public healthcare provider. During 2017-2020, resistance in isolates from urogenital sites of 433 patients was 64.7% (95% CI: 59.5-69.6%; range: 43.9-78.7%) for ciprofloxacin, 50.7% (95% CI: 45.3-56.1%; range: 41.3-70.4%) for tetracycline, and 30.8% (95% CI: 26.3-35.6%; range: 26.7-35.8%) for benzylpenicillin. Percentage of isolates non-susceptible to azithromycin was 4.1% (95% CI: 2.0-7.4%; range: 2.7-4.8%) and all (100%) isolates were susceptible to ceftriaxone. Two (1.6%) isolates from 2019 and one (2.2%) isolate from 2020 had high-level resistance to azithromycin (MIC $\geq$ 256 mg/L). Overall, 1.0% (4/418) of isolates had a ceftriaxone MIC of 0.25 mg/L, which is at the ceftriaxone susceptibility breakpoint (MIC $\leq$ 0.25 mg/L). Treatment with ceftriaxone 250 mg plus azithromycin 1 g can continuously be recommended for gonorrhoea therapy in Qatar. Continued quality-assured gonococcal AMR surveillance is warranted in EMR.

Keywords: *Neisseria gonorrhoeae*, antimicrobial, susceptibility, resistance, sexually transmitted infection, epidemiology.

INTRODUCTION

Gonorrhoea is a common sexually transmitted infection (STI) caused by the bacterium, *Neisseria gonorrhoeae* (gonococcus) [1, 2]. Infection by *N. gonorrhoeae* is associated with cervicitis, pelvic inflammatory disease, ectopic pregnancy, and infertility in women [3-5] and urethritis, epididymitis, and infertility (rare) in men, as well as extragenital infections in both genders [3, 6-8]. In 2016, the World Health Organization (WHO) estimated 87 million new global urogenital gonorrhoea cases each year [9], and WHO has called for achieving a 90% reduction in gonorrhoea incidence by 2030 [10].

Management and control of gonorrhoea have been substantially compromised by widespread antimicrobial resistance (AMR), including international spread of multidrug-resistant and extensively drug-resistant strains with resistance to the last-line, extended-spectrum cephalosporins (ESCs) [2, 11-13]. Resistance had emerged previously to sulphonamides, penicillins, tetracyclines, macrolides, fluoroquinolones, and early-generation cephalosporins [11, 14-16]. In 2012, WHO launched a global action plan to control the spread and impact of AMR in *N. gonorrhoeae* [16], and in 2017 WHO declared gonococcal AMR as a global high priority [17].

One key priority of the WHO global action plan is to enhance gonococcal AMR surveillance globally. Consequently, the WHO's Global Gonococcal Antimicrobial Surveillance Programme (GASP), initially stabled in 1990[18], was revitalized and strengthened [11, 13]. WHO GASP is identifying emerging AMR, monitoring AMR trends, and informing refinements of global, regional, and national gonorrhoea treatment guidelines, as well as public health strategies and policies developed by WHO and other organisations [11]. WHO recommends that treatment guidelines be refined based on data from recent and quality-assured gonococcal AMR surveillance and that use of an antimicrobial in empiric treatment is be discontinued when the rate of therapeutic

failures and/or AMR reach 5% [11, 13, 16, 19]. However, exceedingly limited data regarding gonococcal AMR have been available in several WHO regions, especially in the WHO African and Eastern Mediterranean Regions (‘Arab World’, including the Middle East and North Africa) [11, 13].

Qatar is an Arab country located in the Middle East with a resident population of 2.8 million people [20]. However, 89% of the population are expatriates from over 150 countries [21, 22]. About 60% of the population consists of expatriate craft and manual workers, typically working in mega-development projects [23], who are predominantly young (20-49 years of age), male, and single [24]. The extensive multi-national diversity of this population and its frequent travel between country of origin and Qatar may yield an unusual epidemiological situation for transmission of *N. gonorrhoeae* strains originating from different parts of the world. Thus Qatar provides a unique setting for gonococcal AMR surveillance.

The objectives of this study were to initiate a gonococcal AMR surveillance programme, quality assured in accordance with WHO standards in Qatar, and to investigate the antimicrobial susceptibility of *N. gonorrhoeae* isolates in this country, thereby informing the national STI treatment guidelines in Qatar, as well as contributing to the WHO GASP [11, 13] at a critical time for gonococcal AMR surveillance. With the very limited gonococcal AMR surveillance to date in the WHO Eastern Mediterranean Region [11, 13], this study makes the largest contribution to this surveillance effort from a region that constitutes about 10% of the global population [25].

MATERIAL AND METHODS

Study population

All consecutive viable gonococcal isolates cultured from January 1, 2017 to August 30, 2020 at the Microbiology Laboratory at Hamad Medical Corporation (HMC), a national public healthcare provider in Qatar, were included in the study. Gonococcal isolates (n=433) were from 433 patients (or episodes of infection) with urogenital gonorrhoea. Demographic data (nationality, gender, and age) were collected, but no personal identifiers were available in the study. All patients were aimed to be treated in accordance with the national STI Screening and Prevention Guidelines that implement the United States Centers for Disease Control and Prevention (CDC) Sexually Transmitted Diseases Treatment Guidelines [26].

Urethral swab specimens from males and cervical swab specimens from females were collected in Amies transportation medium (International for Medical Equipment and Supplies, Doha, Qatar).

Culture of *Neisseria gonorrhoeae*

All swabs were transported in ≤ 12 h to the laboratory and inoculated on selective chocolate culture medium (International for Medical Equipment and Supplies, Doha, Qatar), followed by incubation in $5 \pm 1\%$ CO₂-enriched humid atmosphere at $36 \pm 1^\circ\text{C}$ for 24 h, and if negative, for an additional 24 h. Suspected colonies were verified as *N. gonorrhoeae* using an oxidase test, Bruker Maldi Biotyper (Bruker Daltonik, Bremen, Germany), and Phadebact Monoclonal GC Test (MKL Diagnostic AB, Sollentuna, Sweden). Isolates were stored in a Microbank cryovial system that incorporates 25 treated beads and a proprietary cryopreservative (Pro-Lab Diagnostics, Cheshire, UK) at -80°C .

Antimicrobial susceptibility testing

Minimum inhibitory concentrations (MICs; mg/L) of five antimicrobials (ceftriaxone,

azithromycin, ciprofloxacin, tetracycline, and benzylpenicillin) were determined using Etest (bioMerieux, Marcy-l'Etoile, France), in accordance with the manufacturer's instructions. Azithromycin was only tested in 2018-2020 and some isolates were not tested against all antimicrobials, i.e. because they were not requested in routine diagnostics, because of a temporary lack of reagents, such as Etest strips, and/or because the isolates were not viable for subsequent antimicrobial susceptibility testing. MIC values were reported and interpreted using whole MIC doubling dilutions, and, where available, clinical breakpoints for susceptibility (S) and resistance (R), according to the United States Clinical Laboratory and Standards Institute (CLSI) [27]. For ceftriaxone and azithromycin, no clinical resistance breakpoints exist and only the recommended susceptibility breakpoints could be used [27]. β -lactamase production was identified using BD BBL Cefinase paper discs (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). The *N. gonorrhoeae* ATCC 49226 international reference strain was used for quality control. The STROBE checklist can be found in Table S1 of Supplementary Information.

RESULTS

Patients and characteristics of *Neisseria gonorrhoeae* isolates

N. gonorrhoeae isolates (one per patient or gonorrhoea episode) from urogenital sites of 433 patients were examined; 418 (96.5%) were from males and 15 (3.5%) were from females. The patients represented 32 nationalities, but most patients were Qatari (67.2%). All other nationalities each accounted for <10% of the isolates. The median age for the males was 24.0 years (mean: 26.0 years, range: 13-77 years) and for the females it was 32.0 years (mean: 36.8 years, range: 24-60 years).

Antimicrobial susceptibility of *Neisseria gonorrhoeae* isolates

Results of antimicrobial susceptibility testing of all *N. gonorrhoeae* isolates (n=433) are listed in Table S2 of Supplementary Information and are summarised in Table 1.

Overall, in 2017-2020, resistance to ciprofloxacin, tetracycline, and benzylpenicillin was 64.7% (95% confidence interval (CI): 59.5-69.6%; range during 2017-2020: 43.9-78.7%), 50.7% (95% CI: 45.3-56.1%; range: 41.3-70.4%), and 30.8% (95% CI: 26.3-35.6%; range: 26.7-35.8%), respectively. The percentage of isolates non-susceptible to azithromycin was 4.1% (95% CI: 2.0-7.4%; range: 2.7-4.8%) and all (100%) isolates were susceptible to ceftriaxone (Table 1).

MIC distributions for ceftriaxone and azithromycin, included in the internationally recommended first-line, dual antimicrobial therapies [2, 14], are presented in Fig. 1. In total, 1.0% (4/418) of isolates had a ceftriaxone MIC of 0.25 mg/L, which is at the ceftriaxone susceptibility breakpoint [$\text{MIC} \leq 0.25 \text{ mg/L}$ [27]]: 1.9% (2/108) in 2017, 0.9% (1/113) in 2019, and 2.2% (1/46) in 2020. The percentage of isolates with ceftriaxone $\text{MIC} \leq 0.016 \text{ mg/L}$ was 86.6%. Most isolates (>95% having a MIC of <2 mg/L) belonged to the azithromycin MIC wild-type distribution (Fig. 1). Notably, two (1.6%) isolates from 2019 and one (2.2%) isolate from 2020 had a high-level resistance to azithromycin ($\text{MIC} \geq 256 \text{ mg/L}$).

DISCUSSION

AMR in *N. gonorrhoeae* remains a global public health concern, compromising management and control of gonorrhoea, and enhanced, quality-assured gonococcal AMR surveillance internationally is imperative. However, in the most recently published WHO GASP data (from 2015-2016) only one (4.8%) member state (Pakistan) in the WHO Eastern Mediterranean Region

provided AMR data, and only 64 gonococcal isolates were examined [13]. In the present study, we substantially increased the available gonococcal AMR data from this WHO region, and provided AMR data for 433 isolates (five antimicrobials) cultured in Qatar in 2017-2020, which will be available for the WHO GASP. All antimicrobial susceptibility testing was also based on MIC determination, that is, Etest was used, which is recommended in the WHO GASP [11, 13].

High levels of resistance to ciprofloxacin, tetracycline, and benzylpenicillin were found. It is notable that resistance to ciprofloxacin was very high at 64.7%, which is similar to the high levels reported in several other WHO regions [11, 13]. Despite high levels of ciprofloxacin resistance, this antimicrobial or other fluoroquinolones remain in use for empirical treatment of gonorrhoea in many countries. This use needs to be abandoned and ciprofloxacin should only be used for treatment of gonorrhoea when the infection has been proven ciprofloxacin-susceptible as a result of laboratory testing [28].

No resistance to ceftriaxone was found among isolates in Qatar in 2017-2020 and only a small proportion (4.1%) of isolates demonstrated resistance to azithromycin. Accordingly, current first-line empiric treatment in Qatar, using ceftriaxone and azithromycin based on the United States CDC Sexually Transmitted Diseases Treatment Guidelines [26], remains an appropriate treatment, which additionally eradicates concomitant *Chlamydia trachomatis* infection and many *Mycoplasma genitalium* infections. Nevertheless, it is concerning that two isolates from 2019 and one isolate from 2020 in Qatar had high-level resistance to azithromycin ($\text{MIC} \geq 256 \text{ mg/L}$). Furthermore, recently published new recommendations for gonorrhoea treatment (ceftriaxone 500 mg monotherapy) in the United States CDC Sexually Transmitted Diseases Treatment Guidelines [29] will be considered.

The limitations of the present study included the lack of detailed epidemiological information of all gonorrhoea cases and uncertainties regarding the representativeness of the examined gonorrhoea cases. Individuals diagnosed with gonorrhoea at HMC, a national public healthcare provider, were examined, but we did not access any cases being managed in the private sector or at other public healthcare facilities, such as the Qatar Red Crescent Society, the main healthcare provider for craft and manual workers. Nevertheless, 32 nationalities were represented, which suggests that some expatriate craft and manual workers were represented. Only urogenital samples were collected. Azithromycin susceptibility testing was not conducted prior to 2018 and some of the isolates were not examined for susceptibility to all antimicrobials, because they were not requested in routine diagnostics, because of temporary lack of reagents, such as Etest strips, and/or because the isolates were not viable for subsequent antimicrobial susceptibility testing. Finally, the 2016 WHO *N. gonorrhoeae* reference strains [30] were not used for quality assurance and control; however, these strains are now available for use in AMR surveillance.

In conclusion, high levels of resistance to ciprofloxacin, tetracycline, and benzylpenicillin were found in Qatar, but less resistance to azithromycin and none to ceftriaxone. Treatment with ceftriaxone 250 mg plus azithromycin 1 g can be recommended for gonorrhoea therapy in Qatar, but the recently recommended ceftriaxone 500 mg monotherapy [29] will also be considered. Continued and enhanced quality-assured gonococcal AMR surveillance is essential in Qatar and other countries in the WHO Eastern Mediterranean Region. Whole-genome sequencing of *N. gonorrhoeae* isolates is also in progress to enhance understanding of *N. gonorrhoeae* AMR determinants and transmission of *N. gonorrhoeae*, as well as its resistance in different subpopulations in Qatar, compared with the international population.

Acknowledgements The authors are grateful for the administrative support of Ms. Adona Canlas.

Contributors LJA, MU, MA-M, and EBE conceived and designed the study. EBE and AP conducted the laboratory work and antimicrobial susceptibility testing. MU and HC conducted the statistical analyses. MU and LJA with MA-M, EBE, and HC wrote the first draft of the article. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript.

Funding The authors are grateful for the support provided by the Biomedical Research Program and infrastructure support provided by the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine – Qatar. The statements made herein are solely the responsibility of the authors.

Competing interests None declared.

Patient consent for publication Not required.

Ethical approval The study was approved by the Weill Cornell Medicine - Qatar and Hamad Medical Corporation Institutional Review Boards. The study was conducted following the ethics review boards guidelines and regulations. Waiver of consenting was granted as per the study design, retrospective collection of deidentified gonococcal isolates.

Data availability statement All relevant data are available within the manuscript and the supplementary material.

REFERENCES

1. Hook III EW, Handsfield HH. Gonococcal infections in the adult. In: Holmes K, Sparling P, Stamm W, Piot P, Wasserheit J, Corey L, et al., editors. Sexually Transmitted Diseases. 4th ed. New York, NY: McGraw-Hill Education; 2007. p. 627-45.
2. Unemo M, Seifert HS, Hook EW, 3rd, Hawkes S, Ndowa F, Dillon JR. Gonorrhoea. *Nat Rev Dis Primers*. 2019;5(1):79. doi: 10.1038/s41572-019-0128-6. PubMed PMID: 31754194.
3. Centers for Disease Control and Prevention. Gonorrhea- CDC Fact Sheet (Detailed version) 2017 [updated September 26, 2017; cited 2017 18 December]. Available from: <https://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea-detailed.htm>.
4. Reekie J, Donovan B, Guy R, Hocking JS, Kaldor JM, Mak DB, et al. Risk of Pelvic Inflammatory Disease in Relation to Chlamydia and Gonorrhea Testing, Repeat Testing, and Positivity: A Population-Based Cohort Study. *Clin Infect Dis*. 2018;66(3):437-43. Epub 2017/11/15. doi: 10.1093/cid/cix769. PubMed PMID: 29136127.
5. Walker CK, Sweet RL. Gonorrhea infection in women: prevalence, effects, screening, and management. *Int J Womens Health*. 2011;3:197-206. Epub 2011/08/17. doi: 10.2147/IJWH.S13427. PubMed PMID: 21845064; PubMed Central PMCID: PMC3150204.
6. Ness RB, Markovic N, Carlson CL, Coughlin MT. Do men become infertile after having sexually transmitted urethritis? An epidemiologic examination. *Fertility and sterility*. 1997;68(2):205-13. Epub 1997/08/01. doi: 10.1016/s0015-0282(97)81502-6. PubMed PMID: 9240243.
7. Ochsendorf FR. Sexually transmitted infections: impact on male fertility. *Andrologia*. 2008;40(2):72-5. Epub 2008/03/14. doi: 10.1111/j.1439-0272.2007.00825.x. PubMed PMID: 18336453.
8. Wang YC, Chung CH, Chen JH, Chiang MH, Ti Y, Tsao CH, et al. Gonorrhea infection increases the risk of prostate cancer in Asian population: a nationwide population-based cohort study. *Eur J Clin Microbiol Infect Dis*. 2017;36(5):813-21. Epub 2016/12/26. doi: 10.1007/s10096-016-2866-7. PubMed PMID: 28013414.
9. Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. *Bull World Health Organ*. 2019;97(8):548-62P. Epub 2019/08/07. doi: 10.2471/BLT.18.228486. PubMed PMID: 31384073; PubMed Central PMCID: PMC6653813.
10. World Health Organization. Global health sector strategy on Sexually Transmitted Infections, 2016-2021 2016 [April 6, 2021]. Available from: <https://www.who.int/reproductivehealth/publications/rtis/ghss-stis/en/>.
11. Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, et al. Antimicrobial resistance in *Neisseria gonorrhoeae*: Global surveillance and a call for international collaborative action. *PLoS Med*. 2017;14(7):e1002344. Epub 2017/07/08. doi: 10.1371/journal.pmed.1002344. PubMed PMID: 28686231; PubMed Central PMCID: PMC5501266.
12. Lewis DA. Global resistance of *Neisseria gonorrhoeae*: when theory becomes reality. *Curr Opin Infect Dis*. 2014;27(1):62-7. Epub 2013/11/28. doi: 10.1097/QCO.000000000000025. PubMed PMID: 24275696.
13. Unemo M, Lahra MM, Cole M, Galarza P, Ndowa F, Martin I, et al. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. *Sex Health*. 2019;16(5):412-25. doi: 10.1071/SH19023. PubMed PMID: 31437420; PubMed Central PMCID: PMC67035961.
14. Unemo M. Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving *Neisseria gonorrhoeae* continues to challenge. *BMC Infect Dis*. 2015;15:364. doi: 10.1186/s12879-015-1029-2. PubMed PMID: 26293005; PubMed Central PMCID: PMC4546108.

15. Unemo M, Shafer WM. Antimicrobial resistance in *Neisseria gonorrhoeae* in the 21st century: past, evolution, and future. *Clinical microbiology reviews*. 2014;27(3):587-613. Epub 2014/07/02. doi: 10.1128/cmr.00010-14. PubMed PMID: 24982323; PubMed Central PMCID: PMC4135894.
16. World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in *Neisseria gonorrhoeae* 2012 [April 6, 2021]. Available from: <https://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/>.
17. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics 2017 [April 6, 2021]. Available from: <https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/>.
18. World Health Organization. Global surveillance network for gonococcal antimicrobial susceptibility. WHO/VDT/90.452. Unpublished 1990 [April 6, 2021]. Available from: <https://apps.who.int/iris/handle/10665/60725>.
19. Joint United Nations Programme on HIV/AIDS (UNAIDS)/World health Organization (WHO). Sexually transmitted diseases: policies and principles for prevention and care 1999 [April 6, 2021]. Available from: https://data.unaids.org/publications/irc-pub04/una97-6_en.pdf.
20. Planning and Statistics Authority-State of Qatar. Qatar Monthly Statistics 2021 [April 6, 2021]. Available from: <https://www.psa.gov.qa/en/pages/default.aspx>.
21. Planning and Statistics Authority-State of Qatar. The Simplified Census of Population, Housing & Establishments 2019 [April 6, 2021]. Available from: https://www.psa.gov.qa/en/statistics/Statistical%20Releases/Population/Population/2018/Population_social_1_2018_AE.pdf.
22. Priya Dsouza Communications. Population of Qatar by nationality - 2019 report. <https://priyadsouza.com/population-of-qatar-by-nationality-in-2017/> 2019 [April 6, 2021]. Available from: <https://priyadsouza.com/population-of-qatar-by-nationality-in-2017/>.
23. Planning and Statistics Authority-State of Qatar. Labor force sample survey 2017 [April 6, 2021]. Available from: https://www.psa.gov.qa/en/statistics/Statistical%20Releases/Social/LaborForce/2017/statistical_analysis_labor_force_2017_En.pdf.
24. De Bel-Air F. Demography, Migration, and Labour Market in Qatar: Gulf Labour Markets and Migration; 2018 [April 6, 2021]. Available from: https://www.researchgate.net/publication/323129801_Demography_Migration_and_Labour_Market_in_Qatar-UPDATED_June_2017.
25. United Nations Department of Economic and Social Affairs-Population Dynamics. The 2019 Revision of World Population Prospects 2021 [April 6, 2021]. Available from: <https://population.un.org/wpp/>.
26. Workowski KA, Bolan GA, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep*. 2015;64(RR-03):1-137. PubMed PMID: 26042815; PubMed Central PMCID: PMC45885289.
27. Clinical Laboratory and Standards Institute. Global Laboratory Standards for a Healthier World 2021 [April 6, 2021]. Available from: www.clsi.org.
28. Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. *Int J STD AIDS*. 2020;956462420949126. doi: 10.1177/0956462420949126. PubMed PMID: 33121366.
29. St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, et al. Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(50):1911-6. doi: 10.15585/mmwr.mm6950a6. PubMed PMID: 33332296; PubMed Central PMCID: PMC7745960 Journal Editors form for disclosure of potential conflicts of interest. Lindley Barbee reports a grant from Speedx and from Nabriva, personal fees from Nabriva, and nonfinancial

support from Hologic, outside the submitted work. No other potential conflicts of interest were disclosed.

30. Unemo M, Golparian D, Sanchez-Buso L, Grad Y, Jacobsson S, Ohnishi M, et al. The novel 2016 WHO *Neisseria gonorrhoeae* reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. *J Antimicrob Chemother*. 2016;71(11):3096-108. doi: 10.1093/jac/dkw288. PubMed PMID: 27432602; PubMed Central PMCID: PMC5079299.

Table 1 Antimicrobial susceptibility in *Neisseria gonorrhoeae* isolates (n=433) from Qatar, 2017-2020

Antimicrobials (No. tested)	Susceptible/Intermediate/Resistant (/Non-susceptible), % ^a				
	2017 (n=109)	2018 (n=152)	2019 (n=126)	2020 (n=46)	Total (n=433)
CRO (419)	100/NA/0	100/NA/0	100/NA/0	100/NA/0	100/NA/0
AZM (234)	-	97.3/NA/2.7	95.2/NA/4.8	95.7/NA/4.3	95.9/NA/4.1
CIP (365)	7.5/13.8/78.7	11.6/25.9/62.6	13.3/24.1/62.7	19.5/36.6/43.9	11.8/23.6/64.7
PEN (399)	12.8/51.4/35.8	14.8/58.5/26.7	14.7/53.2/32.1	19.6/52.2/28.3	14.8/54.4/30.8
TET (345)	8.6/21.0/70.4	18.8/36.1/45.1	17.6/36.5/46.0	23.9/34.8/41.3	16.8/32.5/50.7

No., number; CRO, ceftriaxone; AZM, azithromycin; CIP, ciprofloxacin; PEN, benzylpenicillin; TET, tetracycline; NA, not applicable; –, not tested.

^aThe breakpoints (susceptible, resistant) were as follows: ceftriaxone (MIC≤0.25 mg/L, not available), azithromycin (MIC≤1 mg/L, not available), ciprofloxacin (MIC≤0.06 mg/L, MIC≥1 mg/L), benzylpenicillin (MIC≤0.06 mg/L, MIC≥2.0 mg/L) and tetracycline (MIC≤0.25 mg/L, MIC≥2 mg/L).

Supplementary information

First characterisation of antimicrobial susceptibility and resistance of *Neisseria gonorrhoeae* isolates in Qatar, 2017-2020

Muna Al-Maslamani,^{1§} Emad Bashier Ibrahim Elmagboul,^{1,2§} Aslam Puthiyottil,¹ Hiam Chemaitelly,^{3,4} Manoj Kizhakkepeedikayil Varghese,¹ Hamad Eid Al Romaihi,⁵ Mohamed H. Al-Thani,⁵ Abdullatif Al Khal,¹ Magnus Unemo,^{6†*} Laith J. Abu-Raddad^{3,4,7,8†*}

¹Hamad Medical Corporation, Doha, Qatar

²Biomedical Research Center, Qatar University, Doha, Qatar

³Infectious Diseases Epidemiology Group, Weill Cornell Medicine – Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar

⁴World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar

⁵Ministry of Public Health, Doha, Qatar

⁶WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, National Reference Laboratory for Sexually Transmitted Infections, Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

⁷Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York City, New York, USA

⁸Department of Public Health, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar

§Joint first authors.

†Joint senior authors.

Table S1 STROBE checklist of items that should be included in reports of cross-sectional studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	8
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	Table S1 in Supplementary Material
Outcome data	15*	Report numbers of outcome events or summary measures	9, Table 1 and Figure 1
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9
		(b) Report category boundaries when continuous variables were categorized	9, Table 1 and Figure 1
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9, Table 1 and Figure 1
Discussion			
Key results	18	Summarise key results with reference to study objectives	9-10

Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

NA, not applicable.

Table S2 Patient characteristics and antimicrobial susceptibility in *Neisseria gonorrhoeae* isolates (n=433) from Qatar, 2017-2020

Isolate	Year	Sex	Age (years)	Benzylpenicillin		Ceftriaxone		Ciprofloxacin		Tetracycline		Azithromycin	
				MIC	Result	MIC	Result	MIC	Result	MIC	Result	MIC	Result
1	2017	M	20-24	1	I	0.032	S	8	R	-	-	-	-
2	2017	M	45-49	0.38	I	0.012	S	0.38	I	-	-	-	-
3	2017	M	40-44	0.032	S	0.002	S	16	R	0.19	S	-	-
4	2017	M	20-24	1.5	R	0.032	S	4	R	4	R	-	-
5	2017	M	20-24	0.094	I	0.003	S	4	R	-	-	-	-
6	2017	M	20-24	256	R	0.006	S	2	R	3	R	-	-
7	2017	M	35-39	8	R	0.008	S	32	R	-	-	-	-
8	2017	M	25-29	0.064	S	0.004	S	4	R	1.5	R	-	-
9	2017	M	25-29	0.25	I	0.004	S	0.75	R	24	R	-	-
10	2017	M	30-34	0.25	I	0.003	S	8	R	24	R	-	-
11	2017	F	30-34	1	I	0.003	S	0.5	I	16	R	-	-
12	2017	M	20-24	0.75	I	0.023	S	8	R	-	-	-	-
13	2017	M	30-34	1.5	R	0.012	S	32	R	3	R	-	-
14	2017	M	30-34	0.38	I	0.023	S	1.5	R	1.5	R	-	-
15	2017	M	30-34	12	R	0.064	S	1	R	-	-	-	-
16	2017	M	20-24	0.75	I	0.023	S	8	R	-	-	-	-
17	2017	M	15-19	16	R	0.004	S	1	R	-	-	-	-
18	2017	M	25-29	12	R	0.003	S	1.5	R	-	-	-	-
19	2017	M	20-24	0.5	I	0.012	S	6	R	-	-	-	-
20	2017	M	15-19	8	R	0.002	S	2	R	-	-	-	-
21	2017	M	25-29	0.25	I	0.006	S	2	R	-	-	-	-
22	2017	M	20-24	0.125	I	0.012	S	3	R	-	-	-	-
23	2017	M	25-29	0.19	I	0.032	S	8	R	-	-	-	-
24	2017	M	25-29	0.75	I	0.002	S	8	R	-	-	-	-
25	2017	M	30-34	0.016	S	0.002	S	2	R	-	-	-	-
26	2017	M	25-29	0.125	I	0.004	S	0.006	S	-	-	-	-
27	2017	M	20-24	0.19	I	0.012	S	4	R	-	-	-	-
28	2017	M	25-29	0.38	I	0.008	S	2	R	-	-	-	-
29	2017	M	35-39	32	R	0.004	S	1	R	-	-	-	-
30	2017	M	20-24	8	R	0.006	S	1.5	R	-	-	-	-
31	2017	M	20-24	0.064	S	0.006	S	32	R	-	-	-	-
32	2017	M	20-24	0.75	I	0.012	S	6	R	1.5	R	-	-
33	2017	M	25-29	6	R	0.004	S	1.5	R	16	R	-	-
34	2017	F	25-29	4	R	0.003	S	1	R	16	R	-	-
35	2017	F	50-54	0.19	I	0.023	S	3	R	32	R	-	-
36	2017	M	25-29	0.38	I	0.016	S	32	R	-	-	-	-
37	2017	M	15-19	12	R	0.003	S	1	R	1	I	-	-
38	2017	M	25-29	0.5	I	0.012	S	32	R	2	R	-	-
39	2017	M	25-29	0.125	I	0.002	S	4	R	1.5	R	-	-
40	2017	M	15-19	3	R	0.002	S	1.5	R	8	R	-	-
41	2017	M	25-29	32	R	-*	S*	4	R	0.5	I	-	-
42	2017	M	30-34	0.016	S	0.002	S	-	-	16	R	-	-
43	2017	M	20-24	0.064	S	0.003	S	0.002	S	0.25	S	-	-
44	2017	M	35-39	192	R	0.003	S	2	R	24	R	-	-
45	2017	M	20-24	3	R	0.003	S	1.5	R	12	R	-	-
46	2017	M	25-29	0.016	S	0.002	S	0.016	S	1	I	-	-
47	2017	M	20-24	16	R	0.003	S	3	R	6	R	-	-
48	2017	M	20-24	0.016	S	0.003	S	32	R	0.25	S	-	-
49	2017	M	35-39	0.25	I	0.003	S	0.75	R	32	R	-	-
50	2017	M	15-19	0.38	I	0.003	S	0.004	S	0.5	I	-	-
51	2017	M	35-39	0.125	I	0.012	S	8	R	1	I	-	-
52	2017	M	40-44	0.5	I	0.023	S	-	-	32	R	-	-
53	2017	M	30-34	0.25	I	0.002	S	-	-	4	R	-	-
54	2017	M	25-29	0.38	I	0.023	S	-	-	1.5	R	-	-
55	2017	M	30-34	4	R	0.004	S	-	-	16	R	-	-
56	2017	M	15-19	0.25	I	0.012	S	-	-	1.5	R	-	-
57	2017	M	30-34	0.125	I	0.004	S	-	-	0.38	I	-	-
58	2017	M	15-19	0.25	I	0.023	S	-	-	1	I	-	-
59	2017	M	20-24	0.016	S	0.002	S	-	-	0.25	S	-	-

Isolate	Year	Sex	Age (years)	Benzylpenicillin		Ceftriaxone		Ciprofloxacin		Tetracycline		Azithromycin	
				MIC	Result	MIC	Result	MIC	Result	MIC	Result	MIC	Result
60	2017	M	20-24	96	R	0.003	S	-	-	16	R	-	-
61	2017	M	20-24	0.38	I	0.012	S	-	-	0.5	I	-	-
62	2017	M	20-24	1	I	0.19	S	-	-	3	R	-	-
63	2017	M	20-24	1	I	0.006	S	1	R	8	R	-	-
64	2017	F	25-29	0.25	I	0.006	S	2	R	0.25	S	-	-
65	2017	M	20-24	0.125	I	0.016	S	1	R	0.5	I	-	-
66	2017	M	20-24	0.047	S	0.002	S	0.125	I	2	R	-	-
67	2017	M	20-24	0.75	I	0.25	S	0.047	S	0.064	S	-	-
68	2017	M	20-24	0.5	I	0.032	S	6	R	0.75	I	-	-
69	2017	M	15-19	16	R	0.032	S	8	R	12	R	-	-
70	2017	M	30-34	1	I	0.032	S	6	R	2	R	-	-
71	2017	M	25-29	0.016	S	0.002	S	4	R	0.38	I	-	-
72	2017	M	25-29	2	R	0.003	S	8	R	-	-	-	-
73	2017	M	15-19	0.125	I	0.002	S	1	R	12	R	-	-
74	2017	M	30-34	0.125	I	0.003	S	0.5	I	-	-	-	-
75	2017	M	15-19	8	R	0.004	S	0.75	R	16	R	-	-
76	2017	M	15-19	2	R	0.003	S	3	R	-	-	-	-
77	2017	M	25-29	0.25	I	0.016	S	2	R	-	-	-	-
78	2017	M	15-19	0.38	I	0.016	S	2	R	1	I	-	-
79	2017	M	20-24	4	R	0.004	S	-	-	32	R	-	-
80	2017	M	25-29	0.064	S	0.003	S	0.75	R	-	-	-	-
81	2017	M	15-19	0.125	I	0.004	S	0.75	R	16	R	-	-
82	2017	M	20-24	4	R	0.004	S	-	-	24	R	-	-
83	2017	M	25-29	8	R	0.003	S	-	-	12	R	-	-
84	2017	F	60-64	0.25	I	0.003	S	0.002	S	16	R	-	-
85	2017	M	35-39	0.064	S	0.003	S	0.003	S	0.5	I	-	-
86	2017	M	20-24	3	R	0.003	S	0.5	I	12	R	-	-
87	2017	M	20-24	2	R	0.008	S	1	R	16	R	-	-
88	2017	M	15-19	0.5	I	0.047	S	2	R	1	I	-	-
89	2017	M	20-24	0.5	I	0.047	S	4	R	1.5	R	-	-
90	2017	M	25-29	0.125	I	0.003	S	0.75	R	16	R	-	-
91	2017	M	25-29	0.094	I	0.002	S	0.75	R	16	R	-	-
92	2017	M	15-19	6	R	0.004	S	0.75	R	2	R	-	-
93	2017	M	25-29	0.125	I	0.002	S	0.75	R	0.5	I	-	-
94	2017	M	15-19	256	R	0.004	S	0.75	R	16	R	-	-
95	2017	M	15-19	0.38	I	0.032	S	8	R	1	I	-	-
96	2017	M	30-34	4	R	0.002	S	0.75	R	12	R	-	-
97	2017	M	15-19	0.064	S	0.008	S	0.38	I	16	R	-	-
98	2017	M	15-19	2	R	0.002	S	0.38	I	1.5	R	-	-
99	2017	M	20-24	4	R	0.003	S	0.38	I	6	R	-	-
100	2017	M	25-29	0.125	I	0.004	S	0.38	I	16	R	-	-
101	2017	M	15-19	0.75	I	0.047	S	4	R	1.5	R	-	-
102	2017	M	20-24	8	R	0.004	S	32	R	16	R	-	-
103	2017	M	15-19	0.125	I	0.008	S	0.38	I	0.25	S	-	-
104	2017	M	15-19	12	R	0.002	S	0.25	I	12	R	-	-
105	2017	M	20-24	0.38	I	0.008	S	1.5	R	0.75	I	-	-
106	2017	M	20-24	8	R	0.125	S	0.38	I	12	R	-	-
107	2017	M	15-19	8	R	0.003	S	0.38	I	24	R	-	-
108	2017	M	15-19	0.5	I	0.023	S	3	R	1.5	R	-	-
109	2017	M	15-19	2	R	0.023	S	2	R	2	R	-	-
110	2018	M	30-34	4	R	0.002	S	0.012	S	8	R	-	-
111	2018	M	25-29	-	-	0.003	S	0.38	I	3	R	-	-
112	2018	M	20-24	6	R	0.003	S	0.75	R	8	R	-	-
113	2018	M	30-34	4	R	0.002	S	0.38	I	0.75	I	-	-
114	2018	M	15-19	0.38	I	0.012	S	1	R	0.5	I	-	-
115	2018	M	15-19	0.19	I	0.002	S	0.002	S	0.5	I	-	-
116	2018	M	25-29	0.38	I	0.023	S	1.5	R	0.75	I	-	-
117	2018	M	20-24	0.38	I	0.032	S	32	R	1	I	-	-
118	2018	M	20-24	0.19	I	0.016	S	2	R	0.75	I	-	-
119	2018	M	15-19	0.094	I	0.002	S	1	R	12	R	-	-
120	2018	M	30-34	0.38	I	0.016	S	1	R	0.75	I	-	-
121	2018	M	20-24	0.38	I	0.006	S	0.25	I	6	R	-	-
122	2018	M	15-19	24	R	0.004	S	0.5	I	12	R	-	-

Isolate	Year	Sex	Age (years)	Benzylpenicillin		Ceftriaxone		Ciprofloxacin		Tetracycline		Azithromycin	
				MIC	Result	MIC	Result	MIC	Result	MIC	Result	MIC	Result
123	2018	M	15-19	8	R	0.004	S	0.5	I	16	R	-	-
124	2018	M	15-19	-	-	0.008	S	1.5	R	0.25	S	-	-
125	2018	M	30-34	-	-	0.002	S	0.002	S	6	R	-	-
126	2018	M	30-34	2	R	0.002	S	0.19	I	0.125	S	-	-
127	2018	M	20-24	0.38	I	0.008	S	0.75	R	0.25	S	-	-
128	2018	M	30-34	4	R	0.002	S	0.75	R	6	R	-	-
129	2018	M	20-24	0.75	I	0.032	S	4	R	1	I	-	-
130	2018	M	45-49	-	-	0.002	S	1.5	R	0.38	I	-	-
131	2018	M	30-34	0.38	I	0.016	S	2	R	1.5	R	-	-
132	2018	M	15-19	0.38	I	0.003	S	12	R	0.5	I	-	-
133	2018	M	25-29	0.5	I	0.016	S	4	R	1	I	-	-
134	2018	M	15-19	-	-	0.003	S	0.002	S	16	R	-	-
135	2018	M	20-24	0.75	I	0.023	S	2	R	1	I	-	-
136	2018	M	25-29	0.064	S	0.003	S	0.5	I	8	R	-	-
137	2018	M	15-19	16	R	0.002	S	1	R	12	R	-	-
138	2018	M	20-24	-	-	0.002	S	0.38	I	16	R	-	-
139	2018	M	30-34	256	R	0.003	S	0.19	I	8	R	-	-
140	2018	M	20-24	192	R	0.002	S	1.5	R	16	R	-	-
141	2018	M	30-34	0.5	I	0.023	S	2	R	0.75	I	-	-
142	2018	M	25-29	0.25	I	0.006	S	2	R	0.75	I	-	-
143	2018	M	25-29	0.094	I	0.002	S	0.002	S	24	R	-	-
144	2018	M	15-19	0.38	I	0.008	S	0.125	I	16	R	-	-
145	2018	M	15-19	0.38	I	0.003	S	8	R	0.75	I	-	-
146	2018	M	25-29	0.19	I	0.012	S	4	R	0.75	I	-	-
147	2018	M	15-19	16	R	0.002	S	0.38	I	12	R	-	-
148	2018	M	15-19	32	R	0.003	S	2	R	16	R	-	-
149	2018	M	45-49	3	R	0.006	S	2	R	24	R	-	-
150	2018	M	40-44	0.016	S	0.002	S	3	R	0.19	S	-	-
151	2018	M	30-34	0.016	S	0.002	S	4	R	0.25	S	-	-
152	2018	M	15-19	0.25	I	0.008	S	2	R	0.5	I	-	-
153	2018	M	20-24	0.016	S	0.002	S	0.002	S	0.19	S	-	-
154	2018	M	25-29	0.047	S	0.002	S	0.5	I	3	R	-	-
155	2018	M	15-19	0.5	I	0.012	S	3	R	0.5	I	-	-
156	2018	M	25-29	16	R	0.003	S	1	R	0.75	I	-	-
157	2018	M	20-24	0.094	I	0.003	S	0.5	I	8	R	-	-
158	2018	M	30-34	0.19	I	0.012	S	4	R	1	I	-	-
159	2018	M	30-34	1	I	0.032	S	4	R	1.5	R	-	-
160	2018	M	25-29	0.5	I	0.023	S	6	R	1	I	-	-
161	2018	M	25-29	0.19	I	0.012	S	1	R	0.75	I	-	-
162	2018	M	40-44	0.19	I	0.003	S	0.75	R	32	R	-	-
163	2018	M	30-34	16	R	0.002	S	0.5	I	-	-	-	-
164	2018	M	25-29	0.75	I	0.012	S	2	R	-	-	-	-
165	2018	M	25-29	1	I	0.064	S	4	R	-	-	-	-
166	2018	M	20-24	0.19	I	0.003	S	-	-	0.38	I	-	-
167	2018	M	30-34	1.5	R	0.008	S	-	-	1.5	R	-	-
168	2018	M	20-24	256	R	0.004	S	2	R	2	R	-	-
169	2018	M	30-34	0.064	S	0.002	S	0.19	I	0.25	S	-	-
170	2018	M	30-34	0.38	I	0.003	S	0.25	I	8	R	-	-
171	2018	M	25-29	2	R	0.047	S	12	R	2	R	-	-
172	2018	M	15-19	0.25	I	0.016	S	33	R	1	I	-	-
173	2018	M	15-19	3	R	0.003	S	1.5	R	-	-	-	-
174	2018	M	20-24	0.25	I	0.006	S	1	R	-	-	-	-
175	2018	M	15-19	0.5	I	0.016	S	6	R	-	-	-	-
176	2018	M	30-34	0.094	I	0.002	S	-	-	4	R	-	-
177	2018	M	30-34	2	R	-	-	4	R	0.094	S	-	-
178	2018	M	15-19	0.19	I	0.004	S	0.75	R	24	R	-	-
179	2018	M	15-19	0.5	I	0.023	S	6	R	32	R	-	-
180	2018	M	15-19	0.19	I	0.004	S	0.75	R	24	R	-	-
181	2018	M	15-19	0.5	I	0.023	S	6	R	32	R	-	-
182	2018	M	15-19	0.38	I	0.008	S	-	-	0.75	I	0.25	S
183	2018	M	40-44	0.125	I	0.003	S	32	R	0.75	I	-	-
184	2018	M	20-24	0.125	I	0.002	S	0.002	S	24	R	-	-
185	2018	M	20-24	0.064	S	0.002	S	0.75	R	-	-	-	-

Isolate	Year	Sex	Age (years)	Benzylpenicillin		Ceftriaxone		Ciprofloxacin		Tetracycline		Azithromycin	
				MIC	Result	MIC	Result	MIC	Result	MIC	Result	MIC	Result
186	2018	M	10-14	0.125	I	0.003	S	0.002	S	16	R	0.19	S
187	2018	M	35-39	0.064	S	0.006	S	2	R	-	-	0.047	S
188	2018	M	25-29	0.75	I	0.006	S	0.75	R	0.25	S	2	R
189	2018	F	30-34	0.125	I	0.002	S	4	R	0.5	I	-	-
190	2018	M	15-19	1.5	R	0.023	S	4	R	1.5	R	0.75	S
191	2018	M	25-29	3	R	0.002	S	0.25	I	4	R	0.032	S
192	2018	M	15-19	0.016	S	0.002	S	0.5	I	2	R	0.125	S
193	2018	F	35-39	0.094	I	0.003	S	3	R	0.125	S	0.094	S
194	2018	M	15-19	0.064	S	0.002	S	0.004	S	0.19	S	0.25	S
195	2018	M	15-19	-	-	0.003	S	0.5	I	8	R	0.064	S
196	2018	M	30-34	-	-	0.002	S	1.5	R	16	R	0.19	S
197	2018	M	55-59	0.094	I	0.003	S	0.75	R	0.5	I	0.032	S
198	2018	M	20-24	0.19	I	0.004	S	0.002	S	16	R	0.25	S
199	2018	M	25-29	1.5	R	0.016	S	0.5	I	8	R	0.75	S
200	2018	M	20-24	3	R	0.002	S	0.75	R	0.5	I	0.016	S
201	2018	M	55-59	-	-	0.094	S	8	R	1.5	R	1	S
202	2018	M	20-24	-	-	0.003	S	0.75	R	12	R	0.064	S
203	2018	M	20-24	0.064	S	0.008	S	0.5	I	12	R	0.047	S
204	2018	M	20-24	-	-	0.032	S	4	R	1	I	0.5	S
205	2018	M	15-19	-	-	0.006	S	4	R	0.75	I	0.5	S
206	2018	M	30-34	0.125	I	0.002	S	2	R	0.19	S	0.125	S
207	2018	M	55-59	-	-	0.032	S	4	R	0.125	S	1	S
208	2018	M	15-19	0.5	I	0.003	S	0.38	I	24	R	0.094	S
209	2018	M	40-44	0.75	I	0.008	S	3	R	0.5	I	0.75	S
210	2018	M	15-19	-	-	0.004	S	1.5	R	0.75	I	0.023	S
211	2018	M	20-24	0.38	I	0.008	S*	0.094	I	0.064	S	2	R
212	2018	M	20-24	0.75	I	0.023	S	2	R	0.75	I	0.75	S
213	2018	M	20-24	0.094	I	0.002	S	0.003	S	0.38	I	0.125	S
214	2018	M	40-44	2	R	0.016	S	0.125	I	16	R	0.19	S
215	2018	M	30-34	0.047	S	0.002	S	0.25	I	2	R	0.016	S
216	2018	M	15-19	0.016	S	0.002	S	0.002	S	0.19	S	0.064	S
217	2018	M	20-24	0.38	I	0.023	S	-	-	1	I	-	-
218	2018	M	20-24	0.064	S	0.002	S	0.5	I	12	R	0.75	S
219	2018	M	20-24	0.125	I	0.008	S	1.5	R	0.38	I	0.25	S
220	2018	M	40-44	6	R	0.003	S	0.75	R	0.38	I	0.064	S
221	2018	M	15-19	0.094	I	0.002	S	1	R	8	R	0.032	S
222	2018	M	20-24	0.19	I	0.006	S	0.75	R	0.25	S	0.19	S
223	2018	M	20-24	256	R	0.003	S	6	R	16	R	0.023	S
224	2018	M	15-19	0.75	I	0.016	S	0.125	I	0.75	I	0.5	S
225	2018	M	30-34	0.094	I	0.002	S	1.5	R	0.5	I	0.25	S
226	2018	M	15-19	1	I	0.064	S	0.75	R	12	R	0.19	S
227	2018	M	20-24	0.5	I	0.002	S	0.19	I	0.38	I	0.032	S
228	2018	M	25-29	0.064	S	0.003	S	1.5	R	0.25	S	-	-
229	2018	M	40-44	0.19	I	0.003	S	1.5	R	12	R	0.094	S
230	2018	M	20-24	0.19	I	0.012	S	0.125	I	0.19	S	0.19	S
231	2018	M	15-19	0.19	I	0.023	S	1.5	R	0.19	S	0.25	S
232	2018	M	25-29	0.25	I	0.008	S	1.5	R	0.19	S	0.25	S
233	2018	M	20-24	0.125	I	0.002	S	0.5	I	0.125	S	0.047	S
234	2018	M	45-49	32	R	0.006	S	1.5	R	16	R	0.094	S
235	2018	M	25-29	0.5	I	0.023	S	4	R	0.5	I	0.5	S
236	2018	M	20-24	0.125	I	0.003	S	0.38	I	8	R	0.023	S
237	2018	M	20-24	-	-	0.023	S	4	R	0.75	I	0.38	S
238	2018	M	30-34	-	-	0.003	S	1	R	12	R	0.047	S
239	2018	M	25-29	-	-	0.002	S	0.003	S	0.5	I	0.047	S
240	2018	M	75-79	0.125	I	0.006	S	6	R	0.38	I	0.19	S
241	2018	M	40-44	4	R	0.002	S	0.5	I	6	R	0.023	S
242	2018	M	30-34	16	R	0.002	S	0.5	I	6	R	0.047	S
243	2018	M	20-24	0.19	I	0.004	S	2	R	0.75	I	0.25	S
244	2018	M	35-39	0.125	I	0.006	S	3	R	0.75	I	0.125	S
245	2018	M	25-29	0.064	S	0.002	S	0.38	I	0.25	S	0.125	S
246	2018	M	15-19	4	R	0.002	S	3	R	4	R	0.19	S
247	2018	M	15-19	16	R	0.002	S	0.002	S	0.75	I	0.094	S

Isolate	Year	Sex	Age (years)	Benzylpenicillin		Ceftriaxone		Ciprofloxacin		Tetracycline		Azithromycin	
				MIC	Result	MIC	Result	MIC	Result	MIC	Result	MIC	Result
248	2018	M	25-29	1	I	0.002	S	0.5	I	16	R	0.19	S
249	2018	M	20-24	0.064	S	0.002	S	4	R	0.25	S	0.064	S
250	2018	F	40-44	24	R	0.003	S	0.75	R	12	R	0.094	S
251	2018	M	30-34	0.5	I	0.016	S	16	R	0.75	I	0.094	S
252	2018	M	35-39	0.094	I	0.012	S	12	R	0.25	S	0.094	S
253	2018	M	20-24	4	R	0.002	S	0.25	I	6	R	0.023	S
254	2018	M	40-44	0.75	I	0.003	S	0.064	S	0.75	I	0.094	S
255	2018	M	20-24	4	R	0.002	S	0.38	I	2	R	0.094	S
256	2018	M	20-24	0.5	I	0.012	S	8	R	0.5	I	0.38	S
257	2018	M	15-19	0.032	S	0.002	S	0.002	S	0.19	S	0.016	S
258	2018	F	60-64	1.5	R	0.002	S	0.5	I	3	R	0.125	S
259	2018	M	30-34	0.016	S	0.002	S	4	R	0.125	S	0.125	S
260	2018	M	20-24	0.19	I	0.008	S	3	R	0.5	I	0.094	S
261	2018	M	15-19	0.064	S	0.002	S	0.002	S	0.25	S	0.016	S
262	2019	M	20-24	4	R	0.016	S	0.38	I	0.125	S	0.047	S
263	2019	M	20-24	-	-	0.016	S	0.38	I	3	R	0.032	S
264	2019	M	15-19	-	-	0.016	S	0.25	I	4	R	0.064	S
265	2019	M	20-24	0.75	I	0.016	S	0.002	S	0.38	I	0.064	S
266	2019	M	20-24	0.38	I	0.016	S	3	R	0.75	I	0.5	S
267	2019	M	25-29	8	R	0.016	S	0.25	I	12	R	0.064	S
268	2019	M	20-24	0.19	I	0.016	S	0.004	S	0.5	I	1.5	R
269	2019	M	20-24	1	I	0.016	S	1	R	8	R	0.047	S
270	2019	M	20-24	-	-	0.016	S	-	-	4	R	0.094	S
271	2019	F	25-29	0.094	I	0.016	S	1	R	4	R	0.016	S
272	2019	M	25-29	-	-	0.023	S	-	-	1	I	0.25	S
273	2019	M	15-19	-	-	0.016	S	-	-	0.25	S	0.047	S
274	2019	M	35-39	-	-	0.023	S	4	R	0.5	I	0.25	S
275	2019	M	20-24	-	-	0.032	S	-	-	0.75	I	0.032	S
276	2019	M	15-19	0.047	S	0.016	S	0.002	S	12	R	0.125	S
277	2019	M	30-34	-	-	0.016	S	-	-	0.125	S	0.094	S
278	2019	M	20-24	-	-	0.016	S	16	R	8	R	0.032	S
279	2019	M	15-19	0.75	I	0.016	S	0.002	S	0.25	S	0.094	S
280	2019	M	25-29	0.094	I	0.016	S	1	R	1	I	0.023	S
281	2019	M	25-29	-	-	0.016	S	-	-	0.25	S	0.094	S
282	2019	M	35-39	2	R	0.016	S	0.38	I	0.19	S	0.064	S
283	2019	M	15-19	16	R	0.016	S	0.38	I	24	R	0.032	S
284	2019	M	25-29	-	-	0.016	S	1.5	R	6	R	0.047	S
285	2019	M	20-24	-	-	0.016	S	-	-	0.5	I	0.125	S
286	2019	M	25-29	0.125	I	-	-	-	-	8	R	0.016	S
287	2019	M	40-44	3	R	-	-	-	-	4	R	0.016	S
288	2019	M	25-29	0.75	I	0.023	S	0.023	S	0.5	I	0.064	S
289	2019	M	20-24	16	R	0.023	S	0.75	R	12	R	0.023	S
290	2019	M	20-24	0.25	I	0.008	S	16	R	0.75	I	0.25	S
291	2019	M	15-19	0.047	S	0.016	S	0.002	S	3	R	0.023	S
292	2019	M	20-24	0.064	S	-	-	-	-	0.25	S	0.016	S
293	2019	M	15-19	0.023	S	-	-	-	-	0.032	S	0.064	S
294	2019	M	15-19	-	-	-	-	1.5	R	12	R	0.25	S
295	2019	M	30-34	0.5	I	-	-	2	R	0.75	I	0.5	S
296	2019	M	30-34	0.25	I	-	-	1.5	R	0.38	I	0.25	S
297	2019	M	30-34	6	R	-	-	0.5	I	16	R	0.032	S
298	2019	M	25-29	-	-	-	-	1	R	6	R	0.125	S
299	2019	M	20-24	0.19	I	0.012	S	32	R	-	-	0.5	S
300	2019	M	25-29	0.25	I	0.25	S	4	R	0.5	I	0.38	S
301	2019	M	20-24	0.094	I	0.002	S	-	-	-	-	0.125	S
302	2019	F	35-39	0.75	I	-	-	6	R	1.5	R	0.5	S
303	2019	M	35-39	-	-	-	-	0.75	R	12	R	0.125	S
304	2019	M	35-39	-	-	-	-	3	R	0.25	S	0.25	S
305	2019	M	20-24	0.25	I	0.006	S	-	-	-	-	0.75	S
306	2019	M	20-24	-	-	-	-	0.004	S	0.25	S	8	R
307	2019	M	20-24	256	R	0.008	S	-	-	-	-	0.75	S
308	2019	M	20-24	0.19	I	0.006	S	-	-	0.5	I	0.75	S
309	2019	M	20-24	0.064	S	0.002	S	-	-	-	-	0.064	S
310	2019	M	25-29	0.064	S	0.012	S	-	-	0.5	I	0.75	S

Isolate	Year	Sex	Age (years)	Benzylpenicillin		Ceftriaxone		Ciprofloxacin		Tetracycline		Azithromycin	
				MIC	Result	MIC	Result	MIC	Result	MIC	Result	MIC	Result
311	2019	M	25-29	0.094	I	0.002	S	-	-	16	R	0.19	S
312	2019	M	25-29	0.19	I	0.032	S	-	-	-	-	256	R
313	2019	M	30-34	256	R	0.002	S	-	-	-	-	0.125	S
314	2019	M	15-19	0.094	I	0.002	S	-	-	-	-	0.38	S
315	2019	M	20-24	0.064	S	0.002	S	-	-	-	-	0.5	S
316	2019	M	15-19	0.023	S	0.002	S	-	-	-	-	0.064	S
317	2019	M	15-19	0.016	S	0.002	S	-	-	-	-	0.016	S
318	2019	M	25-29	3	R	0.064	S	-	-	-	-	0.38	S
319	2019	M	15-19	0.25	I	0.004	S	-	-	-	-	0.38	S
320	2019	M	25-29	0.094	I	0.006	S	-	-	-	-	0.38	S
321	2019	M	15-19	256	R	0.003	S	-	-	-	-	0.38	S
322	2019	M	35-39	0.19	I	0.002	S	-	-	-	-	0.38	S
323	2019	F	25-29	0.064	S	0.002	S	-	-	-	-	0.19	S
324	2019	F	35-39	8	R	0.002	S	-	-	-	-	0.125	S
325	2019	M	20-24	0.064	S	0.016	S	-	-	-	-	0.25	S
326	2019	M	20-24	0.125	I	0.004	S	-	-	-	-	0.25	S
327	2019	M	20-24	0.125	I	0.002	S	-	-	-	-	0.19	S
328	2019	M	20-24	24	R	0.002	S	-	-	-	-	0.125	S
329	2019	M	20-24	0.094	I	0.023	S	-	-	-	-	0.125	S
330	2019	M	35-39	0.125	I	0.002	S	-	-	-	-	0.125	S
331	2019	M	30-34	0.38	I	0.016	S	-	-	-	-	0.75	S
332	2019	M	25-29	256	R	0.002	S	0.75	R	-	-	0.125	S
333	2019	M	30-34	1	I	0.023	S	12	R	-	-	2	R
334	2019	M	25-29	0.25	I	0.012	S	-	-	-	-	0.75	S
335	2019	F	20-24	32	R	0.002	S	-	-	-	-	-	-
336	2019	M	20-24	3	R	0.002	S	-	-	-	-	0.047	S
337	2019	M	20-24	0.19	I	0.006	S	1.5	R	-	-	0.5	S
338	2019	M	20-24	0.25	I	0.008	S	-	-	-	-	0.75	S
339	2019	M	20-24	48	R	0.002	S	1	R	-	-	0.125	S
340	2019	M	25-29	1	I	0.002	S	0.5	I	-	-	0.19	S
341	2019	M	30-34	0.5	I	0.002	S	0.75	R	-	-	0.064	S
342	2019	M	20-24	0.19	I	0.004	S	1.5	R	-	-	0.38	S
343	2019	M	15-19	6	R	0.002	S	0.75	R	-	-	0.094	S
344	2019	M	20-24	0.25	I	0.016	S	1.5	R	-	-	0.5	S
345	2019	M	25-29	0.064	S	0.004	S	6	R	-	-	0.094	S
346	2019	M	25-29	3	R	0.002	S	0.25	I	-	-	0.094	S
347	2019	M	40-44	4	R	0.004	S	0.75	R	-	-	0.38	S
348	2019	M	20-24	0.75	I	0.006	S	-	-	-	-	256	R
349	2019	M	25-29	6	R	0.002	S	0.38	I	-	-	0.125	S
350	2019	M	25-29	0.38	I	0.002	S	0.064	S	-	-	0.094	S
351	2019	M	20-24	8	R	0.002	S	0.75	R	-	-	0.125	S
352	2019	M	25-29	0.75	I	0.002	S	4	R	-	-	-	-
353	2019	M	30-34	0.19	I	0.004	S	1.5	R	-	-	0.38	S
354	2019	M	30-34	0.094	I	0.002	S	1	R	-	-	0.125	S
355	2019	M	35-39	0.5	I	0.012	S	0.75	R	-	-	0.38	S
356	2019	M	60-64	24	R	0.004	S	1.5	R	24	R	0.19	S
357	2019	F	30-34	0.75	I	0.002	S	0.25	I	-	-	0.5	S
358	2019	M	30-34	0.094	I	0.002	S	0.19	I	-	-	0.19	S
359	2019	M	15-19	0.25	I	0.002	S	0.008	S	-	-	3	R
360	2019	M	20-24	4	R	0.003	S	0.75	R	0.5	I	0.19	S
361	2019	M	20-24	3	R	0.003	S	1	R	6	R	0.25	S
362	2019	M	25-29	0.75	I	0.008	S	1	R	0.75	I	1	S
363	2019	M	35-39	3	R	0.004	S	2	R	16	R	0.38	S
364	2019	M	15-19	0.016	S	0.002	S	1	R	0.19	S	0.38	S
365	2019	M	25-29	0.38	I	0.012	S	3	R	1	I	1	S
366	2019	M	20-24	6	R	0.002	S	0.25	I	0.5	I	0.25	S
367	2019	M	20-24	1	I	0.002	S	0.023	S	0.125	S	0.016	S
368	2019	M	20-24	8	R	0.002	S	0.25	I	0.5	I	0.19	S
369	2019	M	20-24	0.125	I	0.008	S	2	R	0.75	I	0.5	S
370	2019	M	30-34	0.75	I	0.002	S	0.25	I	24	R	0.19	S
371	2019	M	15-19	0.75	I	0.002	S	1	R	16	R	0.25	S
372	2019	M	20-24	2	R	0.003	S	0.25	I	32	R	0.38	S
373	2019	M	15-19	0.25	I	0.012	S	1.5	R	0.75	I	0.5	S

Isolate	Year	Sex	Age (years)	Benzylpenicillin		Ceftriaxone		Ciprofloxacin		Tetracycline		Azithromycin	
				MIC	Result	MIC	Result	MIC	Result	MIC	Result	MIC	Result
374	2019	M	20-24	0.094	I	0.002	S	0.125	I	4	R	0.19	S
375	2019	M	35-39	0.016	S	0.002	S	3	R	0.25	S	1	S
376	2019	M	20-24	0.094	I	0.002	S	0.5	I	8	R	0.125	S
377	2019	M	25-29	12	R	0.002	S	1	R	0.75	I	0.125	S
378	2019	M	40-44	0.016	S	0.002	S	2	R	0.38	I	0.75	S
379	2019	M	30-34	2	R	0.002	S	1	R	32	R	0.19	S
380	2019	M	20-24	0.064	S	0.002	S	0.002	S	0.5	I	0.5	S
381	2019	M	50-54	0.19	I	0.012	S	4	R	0.75	I	0.75	S
382	2019	M	25-29	0.125	I	0.002	S	1	R	16	R	0.25	S
383	2019	M	15-19	48	R	0.003	S	1.5	R	24	R	0.38	S
384	2019	M	35-39	256	R	0.003	S	1	R	1	I	0.25	S
385	2019	M	15-19	12	R	0.004	S	3	R	24	R	0.5	S
386	2019	M	40-44	0.19	I	0.004	S	0.5	I	16	R	1	S
387	2019	M	20-24	1.5	R	0.002	S	0.5	I	12	R	0.5	S
388	2020	M	20-24	0.25	I	0.003	S	-	-	0.38	I	0.75	S
389	2020	M	35-39	0.047	S	0.002	S	0.002	S	0.125	S	0.094	S
390	2020	M	20-24	0.5	I	0.012	S	-	-	0.75	I	1	S
391	2020	M	30-34	0.38	I	0.003	S	-	-	12	R	0.5	S
392	2020	M	25-29	32	R	0.002	S	0.25	I	8	R	0.064	S
393	2020	M	15-19	32	R	0.002	S	0.5	I	8	R	0.25	S
394	2020	M	30-34	0.125	I	0.002	S	0.5	I	0.38	I	0.25	S
395	2020	M	20-24	0.19	I	0.003	S	0.006	S	0.38	I	2	R
396	2020	M	20-24	32	R	0.004	S	-	-	16	R	0.38	S
397	2020	M	30-34	0.125	I	0.002	S	0.25	I	8	R	0.5	S
398	2020	M	30-34	0.5	I	0.002	S	-	-	12	R	0.19	S
399	2020	M	20-24	0.38	I	0.006	S	1.5	R	0.5	I	1	S
400	2020	M	30-34	2	R	0.003	S	0.25	I	2	R	0.094	S
401	2020	M	15-19	0.25	I	0.016	S	2	R	1	I	1	S
402	2020	M	40-44	0.125	I	0.008	S	0.002	S	0.125	S	0.75	S
403	2020	M	40-44	0.016	S	0.002	S	0.002	S	0.25	S	0.75	S
404	2020	M	15-19	0.75	I	0.002	S	0.5	I	16	R	0.25	S
405	2020	M	25-29	0.016	S	0.002	S	0.002	S	0.094	S	0.094	S
406	2020	M	20-24	0.5	I	0.003	S	1	R	1.5	R	0.25	S
407	2020	M	50-54	0.25	I	0.006	S	0.125	I	4	R	0.5	S
408	2020	M	20-24	3	R	0.003	S	1	R	12	R	0.25	S
409	2020	M	35-39	6	R	0.002	S	0.75	R	0.75	I	0.094	S
410	2020	M	40-44	0.125	I	0.002	S	0.75	R	0.38	I	0.25	S
411	2020	M	35-39	0.125	I	0.002	S	0.004	S	0.75	I	1	S
412	2020	M	20-24	0.016	S	0.002	S	0.002	S	0.5	I	0.5	S
413	2020	M	20-24	1	I	0.19	S	6	R	0.5	I	256	R
414	2020	M	25-29	0.38	I	0.008	S	4	R	0.5	I	0.75	S
415	2020	M	20-24	0.25	I	0.012	S	3	R	1	I	1	S
416	2020	M	25-29	0.047	S	0.012	S	3	R	0.25	S	0.125	S
417	2020	M	25-29	6	R	0.002	S	0.5	I	0.5	I	0.047	S
418	2020	M	15-19	0.25	I	0.002	S	0.19	I	16	R	0.064	S
419	2020	M	20-24	0.064	S	0.002	S	0.75	R	0.25	S	0.19	S
420	2020	M	45-49	0.064	S	0.002	S	0.023	S	2	R	0.125	S
421	2020	M	20-24	0.094	I	0.003	S	1	R	3	R	0.047	S
422	2020	M	25-29	32	R	0.032	S	3	R	16	R	0.094	S
423	2020	M	55-59	2	R	0.002	S	0.5	I	0.25	S	0.016	S
424	2020	M	30-34	0.125	I	0.004	S	6	R	0.25	S	0.064	S
425	2020	M	25-29	12	R	0.004	S	1	R	12	R	0.125	S
426	2020	M	35-39	1	I	0.006	S	0.5	I	0.25	S	0.125	S
427	2020	M	20-24	0.064	S	0.002	S	0.5	I	0.5	I	0.19	S
428	2020	M	45-49	3	R	0.003	S	1.5	R	6	R	0.125	S
429	2020	M	30-34	0.064	S	0.002	S	2	R	0.25	S	0.064	S
430	2020	M	25-29	2	R	0.002	S	0.25	I	0.032	S	0.032	S
431	2020	M	20-24	4	R	0.008	S	0.38	I	6	R	0.25	S
432	2020	M	30-34	0.75	I	0.002	S	0.25	I	8	R	0.125	S
433	2020	M	25-29	0.125	I	0.004	S	2	R	0.5	I	0.25	S

F, female; I, intermediate; M, male; -, not tested; R, resistance; S, susceptibility.

*The specimen was not viable for confirmatory Etest. Accordingly, the susceptibility characterisation was based on whole-genome sequencing and a lack of all known genetic resistance determinants for ceftriaxone in the genome sequence.